Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Evaluation and sensitivity analysis of the effectiveness of unadjuvanted A(H1N1)pdm09 vaccine in hospital workers using multi-center cohort study in Korea.

Lim J, Choi B, Kim J, Kim J, Kim C, Park J, Yoon H, Hong S, Seo J, Ki M.

Vaccine. 2013 May 1;31(19):2381-6. doi: 10.1016/j.vaccine.2013.02.066.

PMID:
23499597
2.

Uptake and effectiveness of monovalent influenza A (H1N1) pandemic 2009 vaccine among healthcare personnel in Kenya, 2010.

Njuguna H, Ahmed J, Oria PA, Arunga G, Williamson J, Kosgey A, Muthoka P, Mott JA, Breiman RF, Katz MA.

Vaccine. 2013 Sep 23;31(41):4662-7. doi: 10.1016/j.vaccine.2013.07.005.

PMID:
23859843
3.

Effectiveness of monovalent 2009 pandemic influenza A virus subtype H1N1 and 2010-2011 trivalent inactivated influenza vaccines in Wisconsin during the 2010-2011 influenza season.

Bateman AC, Kieke BA, Irving SA, Meece JK, Shay DK, Belongia EA.

J Infect Dis. 2013 Apr 15;207(8):1262-9. doi: 10.1093/infdis/jit020.

PMID:
23341536
4.

Impacts on influenza A(H1N1)pdm09 infection from cross-protection of seasonal trivalent influenza vaccines and A(H1N1)pdm09 vaccines: systematic review and meta-analyses.

Yin JK, Chow MY, Khandaker G, King C, Richmond P, Heron L, Booy R.

Vaccine. 2012 May 2;30(21):3209-22. doi: 10.1016/j.vaccine.2012.02.048. Review.

PMID:
22387221
5.

Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination.

Gefenaite G, Tacken M, Bos J, Stirbu-Wagner I, Korevaar JC, Stolk RP, Wolters B, Bijl M, Postma MJ, Wilschut J, Nichol KL, Hak E.

PLoS One. 2013 Jun 20;8(6):e66125. doi: 10.1371/journal.pone.0066125.

6.

Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea.

Song JY, Cheong HJ, Heo JY, Noh JY, Choi WS, Park DW, Lee J, Jeong HW, Kee SY, Kim WJ.

Vaccine. 2011 Feb 4;29(7):1395-8. doi: 10.1016/j.vaccine.2010.12.050.

PMID:
21199701
7.

Prospective hospital-based case-control study to assess the effectiveness of pandemic influenza A(H1N1)pdm09 vaccination and risk factors for hospitalization in 2009-2010 using matched hospital and test-negative controls.

Hellenbrand W, Jorgensen P, Schweiger B, Falkenhorst G, Nachtnebel M, Greutélaers B, Traeder C, Wichmann O.

BMC Infect Dis. 2012 May 31;12:127. doi: 10.1186/1471-2334-12-127.

8.

Seasonal influenza vaccine and protection against pandemic (H1N1) 2009-associated illness among US military personnel.

Johns MC, Eick AA, Blazes DL, Lee SE, Perdue CL, Lipnick R, Vest KG, Russell KL, DeFraites RF, Sanchez JL.

PLoS One. 2010 May 19;5(5):e10722. doi: 10.1371/journal.pone.0010722.

9.

A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season.

Skowronski DM, Janjua NZ, De Serres G, Winter AL, Dickinson JA, Gardy JL, Gubbay J, Fonseca K, Charest H, Crowcroft NS, Fradet MD, Bastien N, Li Y, Krajden M, Sabaiduc S, Petric M.

Clin Infect Dis. 2012 Aug;55(3):332-42. doi: 10.1093/cid/cis431.

PMID:
22539661
10.

The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2).

Valenciano M, Kissling E, Reuss A, Jiménez-Jorge S, Horváth JK, Donnell JM, Pitigoi D, Machado A, Pozo F; I-MOVE Multicentre Case Control Study Team..

Vaccine. 2015 Jun 4;33(24):2813-22. doi: 10.1016/j.vaccine.2015.04.012.

11.

Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine.

Gaglani M, Spencer S, Ball S, Song J, Naleway A, Henkle E, Bozeman S, Reynolds S, Sessions W, Hancock K, Thompson M.

J Infect Dis. 2014 Jun 1;209(11):1705-14. doi: 10.1093/infdis/jit825.

PMID:
24363436
12.

Association between monovalent influenza A (H1N1) pdm09 vaccine and pneumonia among the elderly in the 2009-2010 season in Japan: A case-control study.

Kondo K, Suzuki K, Washio M, Ohfuji S, Fukushima W, Maeda A, Hirota Y; Pneumonia in Elderly People Study Group..

Hum Vaccin Immunother. 2015;11(5):1088-93. doi: 10.1080/21645515.2015.1016668. Erratum in: Hum Vaccin Immunother. 2015;11(10):2510.

13.

Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada s sentinel surveillance network, January 2014.

Skowronski D, Chambers C, Sabaiduc S, De Serres G, Dickinson J, Winter A, Fonseca K, Gubbay J, Charest H, Petric M, Krajden M, Mahmud S, Van Caeseele P, Kwindt T, Eshaghi A, Bastien N, Li Y.

Euro Surveill. 2014 Feb 6;19(5). pii: 20690. Erratum in: Euro Surveill. 2014;19(6):20698.

14.

Pandemic influenza A(H1N1)pdm09 improves vaccination routine in subsequent years: a cohort study from 2009 to 2011.

Tacken MA, Jansen B, Mulder J, Visscher S, Heijnen ML, Campbell SM, Braspenning JC.

Vaccine. 2013 Jan 30;31(6):900-5. doi: 10.1016/j.vaccine.2012.12.002.

PMID:
23246546
15.

2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals.

Rondy M, Launay O, Puig-Barberà J, Gefenaite G, Castilla J, de Gaetano Donati K, Galtier F, Hak E, Guevara M, Costanzo S; European hospital IVE network., Moren A.

Euro Surveill. 2015 Jan 15;20(2). pii: 21011. Erratum in: Euro Surveill. 2015;20(3). pii: 21015. Niesters, Hubert [added].

16.

Effectiveness of the 2010-11 seasonal trivalent influenza vaccine in Spain: cycEVA study.

Jiménez-Jorge S, Savulescu C, Pozo F, de Mateo S, Casas I, Ledesma J, Larrauri A; cycEVA Study Team.; Spanish Influenza Sentinel Surveillance System..

Vaccine. 2012 May 21;30(24):3595-602. doi: 10.1016/j.vaccine.2012.03.048.

PMID:
22472792
17.

Immunogenicity of influenza A(H1N1)pdm09 vaccine and the associated factors on lowered immune response in patients with hepatitis C.

Ohfuji S, Fukushima W, Tamori A, Maeda K, Maeda A, Hirota Y.

Influenza Other Respir Viruses. 2013 May;7(3):456-65. doi: 10.1111/j.1750-2659.2012.00424.x.

18.

Interim estimates of the effectiveness of seasonal trivalent inactivated influenza vaccine in preventing influenza hospitalisations and primary care visits in Auckland, New Zealand, in 2014.

Turner N, Pierse N, Huang QS, Radke S, Bissielo A, Thompson MG, Kelly H; SHIVERS investigation team..

Euro Surveill. 2014 Oct 23;19(42). pii: 20934.

19.

Effectiveness of MF59™ adjuvanted influenza A(H1N1)pdm09 vaccine in risk groups in the Netherlands.

Wijnans L, Dieleman J, Voordouw B, Sturkenboom M.

PLoS One. 2013 Apr 30;8(4):e63156. doi: 10.1371/journal.pone.0063156.

20.

Effectiveness of 1 dose of influenza A (H1N1) 2009 monovalent vaccines in preventing reverse-transcription polymerase chain reaction-confirmed H1N1 infection among school-aged children in maine.

Uzicanin A, Thompson M, Smith P, Chaves SS, Foster L, Dube N, Graitcer S, Jackson R, Ferdinands J, Gargiullo P, Mills D, Monto AS, Shay DK; Maine 2009 Influenza A (H1N1) Vaccine Effectiveness Evaluation Group..

J Infect Dis. 2012 Oct 1;206(7):1059-68.

PMID:
22850120
Items per page

Supplemental Content

Support Center